Menu
Search
|

Menu

Close
X

Array Biopharma Inc ARRY.OQ (NASDAQ Stock Exchange Global Market)

13.66 USD
-- (--)
As of Oct 12
chart
Previous Close 13.66
Open --
Volume --
3m Avg Volume 682,703
Today’s High --
Today’s Low --
52 Week High 20.20
52 Week Low 10.03
Shares Outstanding (mil) 192.24
Market Capitalization (mil) 2,368.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
174
FY17
151
FY16
138
FY15
52
EPS (USD)
FY18
-0.746
FY17
-0.718
FY16
-0.649
FY15
-0.013
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.75
Price to Sales (TTM)
vs sector
15.70
5.74
Price to Book (MRQ)
vs sector
179.97
5.00
Price to Cash Flow (TTM)
vs sector
--
23.28
Total Debt to Equity (MRQ)
vs sector
1,141.85
16.89
LT Debt to Equity (MRQ)
vs sector
1,141.85
12.55
Return on Investment (TTM)
vs sector
-71.65
14.60
Return on Equity (TTM)
vs sector
--
16.33

EXECUTIVE LEADERSHIP

Carrie Cox
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Ron Squarer
Chief Executive Officer, Director, Since 2012
Salary: $600,010.00
Bonus: $402,127.00
Jason Haddock
Chief Financial Officer, Since 2016
Salary: $370,000.00
Bonus: $151,766.00
Andrew Robbins
Chief Operating Officer, Since 2015
Salary: $435,036.00
Bonus: $218,671.00
Nicholas Saccomano
Chief Scientific Officer, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3200 Walnut St
BOULDER   CO   80301-2514

Phone: +1303.3816600

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company's programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC). Its binimetinib and encorafenib are in Phase III trials in advanced cancer patients, including the COLUMBUS trial studying encorafenib in combination with binimetinib in patients with BRAF-mutant melanoma and has initiated BEACON CRC trial to study encorafenib in combination with binimetinib and cetuximab in patients with BRAF V600E-mutant colorectal cancer (BRAFm CRC). Its selumetinib is a mitogen-activated protein kinase (MEK) inhibitor for cancer, which is in Phase III trial. Its advanced clinical-stage drugs include Filanesib, ARRY-797, ASC08/Danoprevir, Ipatasertib/GDC-0068, Motolimod/VTX-2337, LOXO-101, ONT-380/ARRY-380, GDC-0575, GDC-0994 and ARRY-382.

SPONSORED STORIES